Cyclerion Therapeutics (NASDAQ:CYCN) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) posted its earnings results on Monday. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19, FiscalAI reports. Cyclerion Therapeutics had a negative net margin of 77.02% and a negative return on equity of 24.61%. The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.10 million.

Cyclerion Therapeutics Stock Down 4.0%

NASDAQ:CYCN opened at $1.45 on Tuesday. The stock has a market cap of $5.68 million, a P/E ratio of -1.93 and a beta of 0.94. The business’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.69. Cyclerion Therapeutics has a twelve month low of $1.03 and a twelve month high of $3.79.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.